Handa Hiroshi, Saitoh Takayuki, Murakami Hirokazu
Nihon Rinsho. 2015 Jan;73(1):156-61.
Immunomodulatory drugs (IMiDs) including lenalidomide, a single compound shows various pharmacological action such as the stimulation of T cells and natural killer (NK) cells, the suppression hematopoietic tumor proliferation, suppression of neo-vascularisation, and anti-inflammatory action. It has been thought that IMiDs stimulates CD8+ cytotoxic T cells primarily, it is recently shown that they also stimulate CD4+ helper-T cells similarly. Lenalidomide stimulates T cells and NK-cell through production of Th1 type cytokines IL-2 and IFN-γ from CD4+ helper-T cells. Lenalidomide also activate T cells indirectly by inhibiting regulatory T cells and myeloid derived suppressor cells (MDSC) which inhibit the activation of T cells, but controversy still exist about effects on regulatory T cells.
免疫调节药物（IMiDs），包括来那度胺，单一化合物展现出多种药理作用，如刺激T细胞和自然杀伤（NK）细胞、抑制造血肿瘤增殖、抑制新血管形成以及抗炎作用。过去认为IMiDs主要刺激CD8 + 细胞毒性T细胞，最近研究表明它们同样能刺激CD4 + 辅助性T细胞。来那度胺通过CD4 + 辅助性T细胞产生1型辅助性T细胞（Th1）细胞因子白细胞介素-2（IL-2）和干扰素-γ（IFN-γ）来刺激T细胞和NK细胞。来那度胺还通过抑制调节性T细胞和髓源性抑制细胞（MDSC）间接激活T细胞，而MDSC会抑制T细胞的激活，但关于其对调节性T细胞的影响仍存在争议。
